Abstract
Aim: The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via a web-based data bank system. Methods: We retrospectively analyzed registered data from 3,209 patients since 1999. Results: The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20-54.06 months). Patients ≤40 years demonstrated a longer OS than patients >65 years of age (median OS 71.13 vs. 36.73 months, p < 0.001). Patients who received novel agents at any time during their treatments showed a longer OS than patients who did not (median OS 42.23 vs. 55.50 months, p < 0.001). Response to treatment was associated with OS, with tandem autologous stem cell transplantation (SCT) producing longer OS than single autologous SCT. Conclusions: We demonstrated associations between survival outcomes and treatment modalities as well as baseline disease characteristics in a registry of multiple myeloma patients using a web-based data analysis.
| Original language | English |
|---|---|
| Pages (from-to) | 200-210 |
| Number of pages | 11 |
| Journal | Acta Haematologica |
| Volume | 122 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2009 Nov 1 |
Fingerprint
Keywords
- Multiple myeloma
- Stem cell transplantation, autologous
- Stem cell transplantation, tandem autologous
ASJC Scopus subject areas
- Hematology
Cite this
Clinical features and survival outcomes in patients with multiple myeloma : Analysis of web-based data from the korean myeloma registry. / Kim, Seok Jin; Kim, Kihyun; Kim, Byung Soo; Jo, Deog Yeon; Kang, Hye Jin; Kim, Jin Seok; Mun, Yeung Chul; Kim, Chul Soo; Sohn, Sang Kyun; Eom, Hyeon Seok; Kwak, Jae Yong; Shim, Hyeok; Yoon, Hwi Joong; Jin, Jong Youl; Min, Chang Ki; Shin, Hyunchoon; Won, Jong Ho; Lee, Je Jung; Kwon, Jung Hye; Joo, Young Don; Do, Young Rok; Kim, Sung Hyun; Oh, Sukjoong; Suh, Cheolwon; Lee, Junglim; Yoon, Sung Soo; Kim, Min Kyoung; Bang, Soo Mee; Ryoo, Hun Mo; Kim, Bong Seog; Kim, Hawk; Kim, Hyo Jung; Kim, Yang Soo; Park, Chong Won; Lee, Gyeong Won; Shin, Ho Jin; Park, Seong Kyu; Park, Joon Seong; Kim, Ho Young; Lee, Dong Soon; Lee, Jae Hoon.
In: Acta Haematologica, Vol. 122, No. 4, 01.11.2009, p. 200-210.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical features and survival outcomes in patients with multiple myeloma
T2 - Analysis of web-based data from the korean myeloma registry
AU - Kim, Seok Jin
AU - Kim, Kihyun
AU - Kim, Byung Soo
AU - Jo, Deog Yeon
AU - Kang, Hye Jin
AU - Kim, Jin Seok
AU - Mun, Yeung Chul
AU - Kim, Chul Soo
AU - Sohn, Sang Kyun
AU - Eom, Hyeon Seok
AU - Kwak, Jae Yong
AU - Shim, Hyeok
AU - Yoon, Hwi Joong
AU - Jin, Jong Youl
AU - Min, Chang Ki
AU - Shin, Hyunchoon
AU - Won, Jong Ho
AU - Lee, Je Jung
AU - Kwon, Jung Hye
AU - Joo, Young Don
AU - Do, Young Rok
AU - Kim, Sung Hyun
AU - Oh, Sukjoong
AU - Suh, Cheolwon
AU - Lee, Junglim
AU - Yoon, Sung Soo
AU - Kim, Min Kyoung
AU - Bang, Soo Mee
AU - Ryoo, Hun Mo
AU - Kim, Bong Seog
AU - Kim, Hawk
AU - Kim, Hyo Jung
AU - Kim, Yang Soo
AU - Park, Chong Won
AU - Lee, Gyeong Won
AU - Shin, Ho Jin
AU - Park, Seong Kyu
AU - Park, Joon Seong
AU - Kim, Ho Young
AU - Lee, Dong Soon
AU - Lee, Jae Hoon
PY - 2009/11/1
Y1 - 2009/11/1
N2 - Aim: The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via a web-based data bank system. Methods: We retrospectively analyzed registered data from 3,209 patients since 1999. Results: The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20-54.06 months). Patients ≤40 years demonstrated a longer OS than patients >65 years of age (median OS 71.13 vs. 36.73 months, p < 0.001). Patients who received novel agents at any time during their treatments showed a longer OS than patients who did not (median OS 42.23 vs. 55.50 months, p < 0.001). Response to treatment was associated with OS, with tandem autologous stem cell transplantation (SCT) producing longer OS than single autologous SCT. Conclusions: We demonstrated associations between survival outcomes and treatment modalities as well as baseline disease characteristics in a registry of multiple myeloma patients using a web-based data analysis.
AB - Aim: The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via a web-based data bank system. Methods: We retrospectively analyzed registered data from 3,209 patients since 1999. Results: The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20-54.06 months). Patients ≤40 years demonstrated a longer OS than patients >65 years of age (median OS 71.13 vs. 36.73 months, p < 0.001). Patients who received novel agents at any time during their treatments showed a longer OS than patients who did not (median OS 42.23 vs. 55.50 months, p < 0.001). Response to treatment was associated with OS, with tandem autologous stem cell transplantation (SCT) producing longer OS than single autologous SCT. Conclusions: We demonstrated associations between survival outcomes and treatment modalities as well as baseline disease characteristics in a registry of multiple myeloma patients using a web-based data analysis.
KW - Multiple myeloma
KW - Stem cell transplantation, autologous
KW - Stem cell transplantation, tandem autologous
UR - http://www.scopus.com/inward/record.url?scp=70350543697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350543697&partnerID=8YFLogxK
U2 - 10.1159/000253027
DO - 10.1159/000253027
M3 - Article
VL - 122
SP - 200
EP - 210
JO - Acta Haematologica
JF - Acta Haematologica
SN - 0001-5792
IS - 4
ER -